You have 7 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

TKI

Showing 76 - 100 of 1,196
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Chronic Phase Chronic Myelogenous Leukemia Trial in Detroit, Milwaukee (Asciminib, Imatinib)

Recruiting
  • Chronic Phase Chronic Myelogenous Leukemia
  • Detroit, Michigan
  • +1 more
May 3, 2022

Clear Cell Renal Cell Carcinoma?Resistance to Immunotherapy Trial in Shanghai (AK104(anti-PD-1/CTLA-4 bi-specific antibody

Recruiting
  • Clear Cell Renal Cell Carcinoma、Resistance to Immunotherapy
  • AK104（anti-PD-1/CTLA-4 bi-specific antibody ，intravenously）,lenvatinib（ targeted VEGFR 1-3、FGFR、PDGFRα， small molecule TKI，orally
  • Shanghai, Shanghai, China
    Shanghai Renji Hospital
Sep 12, 2023

NSCLC Trial in Tai'an (Ametinib combined with bevacizumab)

Recruiting
  • Non-small Cell Lung Cancer
  • Ametinib combined with bevacizumab
  • Tai'an, Shandong, China
    The Second Affiliated Hospital of Shandong First Medical Univers
Feb 22, 2023

NSCLC Trial (AK119, AK112, Pemetrexed)

Not yet recruiting
  • NSCLC
  • (no location specified)
Nov 23, 2022

EGFR Positive NSCLC Trial in China (APG-1252, Osimertinib Mesylate Tablets)

Recruiting
  • EGFR Positive Non-small Cell Lung Cancer
  • Guangzhou, Guangdong, China
  • +3 more
Oct 27, 2021

Nonproliferative Diabetic Retinopathy Trial (EYP-1901, Sham IVT)

Not yet recruiting
  • Nonproliferative Diabetic Retinopathy
  • (no location specified)
Aug 3, 2022

Unifying Advanced Treatment With Advanced Imaging

Completed
  • Gastrointestinal Stromal Tumor (GIST)
  • Dual Energy CT
  • Mannheim, Germany
    University Center Mannheim
Apr 6, 2022

Advanced HCC Trial in Beijing (KN046 (PD-L1/CTLA4 BsAb), Ningetinib Tosylate(multi-target TKI))

Terminated
  • Advanced HCC
  • KN046 （PD-L1/CTLA4 BsAb）
  • Ningetinib Tosylate（multi-target TKI）
  • Beijing, Beijing, China
    Chinese Pla General Hospital Chinese Pla Medical School
Oct 26, 2022

Non Small Cell Lung Cancer, Liquid Biopsy, Tyrosine Kinase Inhibitor Trial in Rotterdam

Recruiting
  • Non Small Cell Lung Cancer
  • +2 more
    • Rotterdam, Netherlands
      Erasmus MC
    Feb 2, 2022

    PD-1 Blockade Plus Platinum-based Chemotherapy in EGFR Sensitive

    Completed
    • Non Small Cell Lung Cancer
      • Changsha, Hunan, China
        Hunan Cancer Hospital
      Mar 9, 2022

      Non-clear Renal Cell Carcinoma Trial in Nanjing, Nanning (Toripalimab, Axitinib)

      Recruiting
      • Non-clear Renal Cell Carcinoma
      • Nanjing, Jiangsu, China
      • +1 more
      Mar 13, 2023

      Chronic Myeloid Leukemia Trial in Germany, Netherlands (TKI discontinuation, nilotinib)

      Active, not recruiting
      • Chronic Myeloid Leukemia
      • Freiburg, Baden-Württemberg, Germany
      • +14 more
      Nov 4, 2021

      Non-Squamous NSCLC Trial in Guangzhou (AK112 Injection, Placebo Injection)

      Recruiting
      • Non-Squamous Non-small Cell Lung Cancer
      • AK112 Injection
      • Placebo Injection
      • Guangzhou, Guangdong, China
        Sun Yat-sen University Cancer Center
      May 23, 2022

      NSCLC Stage IV Trial in Taipei (therapeutic thoracic surgery, Afatinib)

      Recruiting
      • NSCLC Stage IV
      • Taipei, Taiwan
      • +1 more
      Mar 8, 2022

      NSCLC Trial (Telisotuzumab Vedotin, Osimertinib, Cisplatin)

      Not yet recruiting
      • Non-Small Cell Lung Cancer
      • Telisotuzumab Vedotin
      • +4 more
      • (no location specified)
      Oct 17, 2023

      Chronic Myeloid Leukemia, Chronic Phase Trial in Spain (Ponatinib 15 MG, Acetylsalicylic acid 100 MG)

      Recruiting
      • Chronic Myeloid Leukemia, Chronic Phase
      • Ponatinib 15 MG
      • Acetylsalicylic acid 100 MG
      • L'Hospitalet De Llobregat, Barcelona, Spain
      • +12 more
      Feb 8, 2022

      Non Small Cell Lung Cancer Trial in Worldwide (Amivantamab, Lazertinib, Zirabev)

      Not yet recruiting
      • Non Small Cell Lung Cancer
      • Angers, France
      • +30 more
      Oct 31, 2022

      NSCLC, Thyroid Tumors Trial (LOXO-260)

      Temporarily not available
      • Carcinoma, Non-Small-Cell Lung
      • Thyroid Neoplasms
      • (no location specified)
      Sep 20, 2022

      Renal Cell Carcinoma Trial in Omaha, Cleveland, Philadelphia (Axitinib)

      Terminated
      Has Results
      • Renal Cell Carcinoma
      • Omaha, Nebraska
      • +2 more
      Jul 26, 2021

      Food Preferences Trial in Wageningen (Dietary intervention)

      Recruiting
      • Food Preferences
      • Dietary intervention
      • Wageningen, Netherlands
        Department of Human Nutrition, Wageningen University
      Jul 19, 2022

      Leptomeningeal Metastasis, Lung Cancer Trial in Hebei (Nimotuzumab)

      Recruiting
      • Leptomeningeal Metastasis
      • Lung Cancer
      • Hebei, Shijiazhuang/hebei, China
      • +1 more
      Apr 18, 2021

      NSCLC Trial in Worldwide (Repotrectinib, Crizotinib)

      Not yet recruiting
      • Carcinoma, Non-Small-Cell Lung
      • Augusta, Georgia
      • +40 more
      Nov 29, 2023

      Resectable Non-Small Cell Lung Cancer Stages IIB-IIIB

      Recruiting
      • Non Small Cell Lung Cancer
      • anti-PD-1 or anti-PD-L1
      • +2 more
      • Shanghai, China
        Oncology Department, Shanghai Chest Hospital
      Jul 26, 2022

      Non Small Cell Lung Cancer Trial in Tianjin (Osimertinib, Bevacizumab Biosimilar IBI305, Carboplatin)

      Recruiting
      • Non Small Cell Lung Cancer
      • Tianjin, Tianjin, China
        Tianjin Medical University Cancer Institute and Hospital
      Aug 18, 2022

      ALK-positive NSCLC in Sweden: Sequencing of ALK Tyrosine Kinase

      Completed
      Has Results
      • ALK-positive NSCLC
      • Sollentuna, Sweden
        Pfizer Innovations AB
      Mar 14, 2022